BFM
KPTI icon

Boothbay Fund Management’s Karyopharm Therapeutics KPTI Stock Holding History

Boothbay Fund Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-213,810
Closed -$1.19M – 2456
2026
Q1 		$1.19M Buy
213,810
+69,182
+48% +$527K 0.02% 860
2025
Q4 		$1.06M Buy
+144,628
New +$885K 0.02% 774
2025
Q1 		– Sell
-6,042
Closed -$61.3K – 1596
2024
Q4 		$61.3K Sell
6,042
-31
-0.5% -$375 ﹤0.01% 1334
2024
Q3 		$75.6K Hold
6,073
– – ﹤0.01% 1479
2024
Q2 		$79K Hold
6,073
– – ﹤0.01% 1369
2024
Q1 		$138K Buy
6,073
+624
+11% +$10.9K ﹤0.01% 1383
2023
Q4 		$70.7K Hold
5,449
– – ﹤0.01% 1485
2023
Q3 		$110K Hold
5,449
– – ﹤0.01% 1552
2023
Q2 		$146K Buy
5,449
+1,355
+33% +$58.4K ﹤0.01% 1550
2023
Q1 		$239K Buy
+4,094
New +$202K ﹤0.01% 1642
2021
Q4 		– Sell
-2,641
Closed -$231K – 2055
2021
Q3 		$231K Buy
2,641
+1,103
+72% +$114K 0.01% 1491
2021
Q2 		$238K Buy
+1,538
New +$223K 0.01% 1415
2019
Q3 		– Sell
-2,455
Closed -$333K – 839
2019
Q2 		$221K Sell
2,455
-9,569
-80% -$768K 0.02% 597
2019
Q1 		$1.05M Buy
+12,024
New +$1.33M 0.1% 219
2018
Q3 		– Sell
-1,360
Closed -$347K – 870
2018
Q2 		$347K Buy
+1,360
New +$336K 0.03% 436

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Boothbay Fund Management's KPTI Position: Q2 2026 in Review

Boothbay Fund Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 213,810 shares — an estimated $1.19M sold.

Boothbay Fund Management first reported a position in KPTI in Q2 2018 and held it in 15 quarters. The position peaked at $1.19M in Q1 2026. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Boothbay Fund Management reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 213,810 Karyopharm Therapeutics shares in Q2 2026, an estimated $1.19M.
  • Boothbay Fund Management first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 15 quarters.
  • Boothbay Fund Management's Karyopharm Therapeutics position peaked at $1.19M in Q1 2026.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.